MX2021012968A - Formulaciones de anticuerpo de baja viscosidad, estables y usos de las mismas. - Google Patents

Formulaciones de anticuerpo de baja viscosidad, estables y usos de las mismas.

Info

Publication number
MX2021012968A
MX2021012968A MX2021012968A MX2021012968A MX2021012968A MX 2021012968 A MX2021012968 A MX 2021012968A MX 2021012968 A MX2021012968 A MX 2021012968A MX 2021012968 A MX2021012968 A MX 2021012968A MX 2021012968 A MX2021012968 A MX 2021012968A
Authority
MX
Mexico
Prior art keywords
aspartate
glutamate
acetate
sulfate
arginine
Prior art date
Application number
MX2021012968A
Other languages
English (en)
Spanish (es)
Inventor
Atul Saluja
Manjori Ganguly
Kelvin Rembert
Yatin Gokarn
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70295163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021012968(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2021012968A publication Critical patent/MX2021012968A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2021012968A 2019-04-23 2020-04-23 Formulaciones de anticuerpo de baja viscosidad, estables y usos de las mismas. MX2021012968A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962837518P 2019-04-23 2019-04-23
EP20305145 2020-02-17
PCT/EP2020/061340 WO2020216847A1 (en) 2019-04-23 2020-04-23 Stable, low-viscosity antibody formulations and uses thereof

Publications (1)

Publication Number Publication Date
MX2021012968A true MX2021012968A (es) 2022-01-18

Family

ID=70295163

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012968A MX2021012968A (es) 2019-04-23 2020-04-23 Formulaciones de anticuerpo de baja viscosidad, estables y usos de las mismas.

Country Status (15)

Country Link
US (1) US20220218607A1 (https=)
EP (1) EP3958896A1 (https=)
JP (2) JP7671697B2 (https=)
KR (1) KR20220004104A (https=)
CN (1) CN114286690A (https=)
AU (1) AU2020262231A1 (https=)
BR (1) BR112021021099A2 (https=)
CA (1) CA3137464A1 (https=)
CO (1) CO2021015561A2 (https=)
IL (1) IL287435A (https=)
MA (1) MA55750A (https=)
MX (1) MX2021012968A (https=)
SG (1) SG11202111740PA (https=)
TW (1) TW202108171A (https=)
WO (1) WO2020216847A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
MX2022006882A (es) * 2019-12-05 2022-11-08 Sanofi Aventis Us Llc Formulaciones de anticuerpos anti-cd38 para administracion subcutanea.
WO2023109928A1 (zh) * 2021-12-16 2023-06-22 上海宝济药业有限公司 抗免疫球蛋白降解酶酶切的Fc变体
WO2024023843A1 (en) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited A pharmaceutical formulation of a therapeuticantibody and preparations thereof
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460944A (en) * 1991-10-28 1995-10-24 Boehringer Mannheim Gmbh Storable protein solution
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5577098B2 (ja) * 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
WO2009120684A1 (en) * 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
BR112012021576A2 (pt) * 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
US9956165B2 (en) * 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2864539C (en) * 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
HUE033369T2 (en) * 2012-11-20 2017-11-28 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
US20160058863A1 (en) * 2014-09-03 2016-03-03 Board Of Regents, The University Of Texas System Low viscosity concentrated protein dispersions
WO2018119142A1 (en) * 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR20190095943A (ko) * 2016-12-22 2019-08-16 사노피 고갈 활성을 갖는 인간화 cxcr3 항체 및 이의 사용 방법

Also Published As

Publication number Publication date
MA55750A (fr) 2022-03-02
AU2020262231A1 (en) 2021-12-16
KR20220004104A (ko) 2022-01-11
IL287435A (en) 2021-12-01
CA3137464A1 (en) 2020-10-29
EP3958896A1 (en) 2022-03-02
JP2022530050A (ja) 2022-06-27
WO2020216847A1 (en) 2020-10-29
CN114286690A (zh) 2022-04-05
SG11202111740PA (en) 2021-11-29
BR112021021099A2 (pt) 2021-12-14
JP7671697B2 (ja) 2025-05-02
TW202108171A (zh) 2021-03-01
JP2025087851A (ja) 2025-06-10
US20220218607A1 (en) 2022-07-14
CO2021015561A2 (es) 2021-12-10

Similar Documents

Publication Publication Date Title
MX2021012968A (es) Formulaciones de anticuerpo de baja viscosidad, estables y usos de las mismas.
EP4650371A3 (en) Antibody-containing preparation
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
EP4233892A3 (en) Stable anti-ifnar1 formulation
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
MX2021002935A (es) Formulacion de anticuerpos contra csf-1r.
ZA202407615B (en) Formulations of dengue virus vaccine compositions
PE20141159A1 (es) Metodos para tratar o prevenir trastornos relacionados con el colesterol
PH12019550249A1 (en) Solid compositions for oral administration
PH12019550107A1 (en) Composition of mannuronic diacid
AR083034A1 (es) ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO
PH12018501243B1 (en) Pharmaceutical composition comprising anti-human tslp receptor antibody
EA201791111A1 (ru) Пероральная регидратационанная композиция и способы
AR096705A1 (es) Composición que comprende ácido glutámico-n,n-diacetato (glda), agua y enzima
EP4653537A3 (en) Rhodopsin gene therapy for regenerating visual function or for preventing deterioration in visual function
BR112018014123A2 (pt) formulação farmacêutica aquosa estável.
MX2021012939A (es) Formulaciones de factor ix liofilizadas.
WO2019221815A8 (en) Compositions of fosaprepitant and methods of preparation
EA202092069A1 (ru) Композиции и способы лечения макулярной дистрофии
MX2021014773A (es) Formas de sales cristalinas de un inhibidor de cinasas.
EA201890018A1 (ru) Композиция для придания формы волосам
AU2020237097A8 (en) Sodium fluorescein as a reversal agent for an anti-fluorescein CAR T cells and fluorescein-phospholipid-ethers or profluorescein-phospholipid-ethers
FI3554474T3 (fi) Mikafungiinikoostumuksia
SA520411881B1 (ar) صياغات إطلاق مديد لتطبيقات داخل المفصل
PH12019550035A1 (en) The beta-caseins and gut microbiota